iScience (Jun 2024)

The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection

  • Hui Wang,
  • Yashoda M. Hosakote,
  • Paul J. Boor,
  • Jun Yang,
  • Yuanyi Zhang,
  • Xiaoying Yu,
  • Casey Gonzales,
  • Corri B. Levine,
  • Susan McLellan,
  • Nicole Cloutier,
  • Xuping Xie,
  • Pei-Yong Shi,
  • Ping Ren,
  • Haitao Hu,
  • Keer Sun,
  • Lynn Soong,
  • Jiaren Sun,
  • Yuejin Liang

Journal volume & issue
Vol. 27, no. 6
p. 110117

Abstract

Read online

Summary: Dysregulated host immune responses contribute to disease severity and worsened prognosis in COVID-19 infection and the underlying mechanisms are not fully understood. In this study, we observed that IL-33, a damage-associated molecular pattern molecule, is significantly increased in COVID-19 patients and in SARS-CoV-2-infected mice. Using IL-33−/− mice, we demonstrated that IL-33 deficiency resulted in significant decreases in bodyweight loss, tissue viral burdens, and lung pathology. These improved outcomes in IL-33−/− mice also correlated with a reduction in innate immune cell infiltrates, i.e., neutrophils, macrophages, natural killer cells, and activated T cells in inflamed lungs. Lung RNA-seq results revealed that IL-33 signaling enhances activation of inflammatory pathways, including interferon signaling, pathogen phagocytosis, macrophage activation, and cytokine/chemokine signals. Overall, these findings demonstrate that the alarmin IL-33 plays a pathogenic role in SARS-CoV-2 infection and provides new insights that will inform the development of effective therapeutic strategies for COVID-19.

Keywords